📊 FEMY Key Takeaways
Is FEMY a Good Investment? Thesis Analysis
Femasys exhibits severe financial distress with massive operating losses (-$13.0M on $1.5M revenue) and deeply negative cash flow (-$14.9M), indicating the company is burning cash at an unsustainable rate. Despite 52% revenue growth, the company lacks profitability at every level and is operating far from cash flow breakeven, with only 4.6 months of cash runway at current burn rates. The negative gross margin contribution to fixed costs and complete absence of path to profitability present extreme risk of capital insufficiency.
Why Buy FEMY? Key Strengths
- Revenue growing 52% year-over-year showing market traction for products
- Positive gross margin of 37.6% indicates underlying product economics are viable
- No long-term debt providing some balance sheet flexibility and avoiding interest burden
FEMY Investment Risks to Consider
- Catastrophic operating losses of -$13.0M against only $1.5M revenue indicating massive operating expense structure misalignment
- Severely negative free cash flow of -$14.9M with only $4.6M cash equivalents, suggesting approximately 3.7 months of runway at current burn rate
- Net margin of -991.8% and operating margin of -876.1% indicate company is nowhere near unit economics breakeven despite revenue growth
- Negative interest coverage of -35.9x reflects inability to service any debt obligations
- Rapid cash depletion threatens ability to fund operations and R&D within 12 months without capital raise or dramatic expense reduction
Key Metrics to Watch
- Operating cash flow trajectory and time to cash depletion at current burn rate
- Quarterly revenue growth sustainability and gross margin consistency
- Operating expense reduction initiatives and path to operating breakeven
- Cash balance and timing of any equity raises or financing events
- Customer acquisition cost relative to lifetime value and unit economics
- Capital expenditure requirements for manufacturing scaling
FEMY Financial Metrics
💡 AI Analyst Insight
FEMASYS INC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
FEMY Profitability Ratios
FEMY vs Healthcare Sector
How FEMASYS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FEMY Overvalued or Undervalued?
Based on fundamental analysis, FEMASYS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FEMY Balance Sheet & Liquidity
FEMY 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: FEMASYS INC's revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.93 indicates the company is currently unprofitable.
FEMY Growth Metrics (YoY)
FEMY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $554.9K | -$4.2M | $-0.10 |
| Q2 2025 | $221.5K | -$4.6M | $-0.16 |
| Q1 2025 | $271.1K | -$3.6M | $-0.17 |
| Q3 2024 | $244.4K | -$4.0M | $-0.24 |
| Q2 2024 | $221.5K | -$2.9M | $-0.21 |
| Q1 2024 | $271.1K | -$2.9M | $-0.17 |
| Q3 2023 | $244.4K | -$3.0M | $-0.25 |
| Q2 2023 | $303.1K | -$2.6M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FEMY Capital Allocation
FEMY SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for FEMASYS INC (CIK: 0001339005)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FEMY
What is the AI rating for FEMY?
FEMASYS INC (FEMY) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FEMY's key strengths?
Claude: Revenue growing 52% year-over-year showing market traction for products. Positive gross margin of 37.6% indicates underlying product economics are viable.
What are the risks of investing in FEMY?
Claude: Catastrophic operating losses of -$13.0M against only $1.5M revenue indicating massive operating expense structure misalignment. Severely negative free cash flow of -$14.9M with only $4.6M cash equivalents, suggesting approximately 3.7 months of runway at current burn rate.
What is FEMY's revenue and growth?
FEMASYS INC reported revenue of $1.5M.
Does FEMY pay dividends?
FEMASYS INC does not currently pay dividends.
Where can I find FEMY SEC filings?
Official SEC filings for FEMASYS INC (CIK: 0001339005) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FEMY's EPS?
FEMASYS INC has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FEMY a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, FEMASYS INC has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FEMY stock overvalued or undervalued?
Valuation metrics for FEMY: ROE of -322.1% (sector avg: 15%), net margin of -991.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FEMY stock in 2026?
Our dual AI analysis gives FEMASYS INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FEMY's free cash flow?
FEMASYS INC's operating cash flow is $-14.5M, with capital expenditures of $385.2K. FCF margin is -1,006.2%.
How does FEMY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -991.8% (avg: 12%), ROE -322.1% (avg: 15%), current ratio 1.16 (avg: 2).